Anti-IgE Antibodies

Ralph Adams; Thomas Allen Ceska; Anna Marie Davies; Alistair James Henry; Xiaofeng Liu; James Michael McDonnell; Brian John Sutton; Marta Katarzyna Westwood

Anti-IgE Antibodies

Ralph Adams (Inventor), Thomas Allen Ceska (Inventor), Anna Marie Davies (Inventor), Alistair James Henry (Inventor), Xiaofeng Liu (Inventor), James Michael McDonnell (Inventor), Brian John Sutton (Inventor), Marta Katarzyna Westwood (Inventor)

Research output: Patent

Abstract

The present invention relates to the area of improved anti-IgE antibodies and antigen binding agents, and compositions thereof, which target IgE, for instance: for use in treating disorders caused by IgE (such as allergic responses, or certain autoimmune responses); and, in particular, disorders caused by the interaction of IgE with the FcεRI receptor. In particular, this invention relates to improved anti-IgE antibodies and antigen binding agents related to novel mutants of omalizumab (Xolair®). The improved anti-IgE antibodies and antigen binding agents of the invention may have improved affinity for IgE and/or an improved interaction with the Cε2 domain of IgE and/or an improved modified epitope on IgE (for instance further involving the Cε2 domain of IgE) and/or the ability to disassociate IgE from the FcεRI receptor for instance at pharmaceutically-relevant concentrations. In one aspect, improved or novel treatments for IgE mediated disorders are disclosed in which IgE is targeted (for instance free IgE and/or IgE complexed with the FcεRI receptor).

Original language	English
Patent number	WO 2017/211928 A1
Priority date	10/06/2016
Filing date	8/06/2017
Publication status	Published - 14 Dec 2017

Access to Document

https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2017211928

Cite this

@misc{6a23ab86424240089205298f4b992af6,

title = "Anti-IgE Antibodies",

abstract = "The present invention relates to the area of improved anti-IgE antibodies and antigen binding agents, and compositions thereof, which target IgE, for instance: for use in treating disorders caused by IgE (such as allergic responses, or certain autoimmune responses); and, in particular, disorders caused by the interaction of IgE with the FcεRI receptor. In particular, this invention relates to improved anti-IgE antibodies and antigen binding agents related to novel mutants of omalizumab (Xolair{\textregistered}). The improved anti-IgE antibodies and antigen binding agents of the invention may have improved affinity for IgE and/or an improved interaction with the Cε2 domain of IgE and/or an improved modified epitope on IgE (for instance further involving the Cε2 domain of IgE) and/or the ability to disassociate IgE from the FcεRI receptor for instance at pharmaceutically-relevant concentrations. In one aspect, improved or novel treatments for IgE mediated disorders are disclosed in which IgE is targeted (for instance free IgE and/or IgE complexed with the FcεRI receptor).",

author = "Ralph Adams and Ceska, {Thomas Allen} and Davies, {Anna Marie} and Henry, {Alistair James} and Xiaofeng Liu and McDonnell, {James Michael} and Sutton, {Brian John} and Westwood, {Marta Katarzyna}",

year = "2017",

month = dec,

day = "14",

language = "English",

type = "Patent",

note = "WO 2017/211928 A1",

}

TY - PAT

T1 - Anti-IgE Antibodies

AU - Adams, Ralph

AU - Ceska, Thomas Allen

AU - Davies, Anna Marie

AU - Henry, Alistair James

AU - Liu, Xiaofeng

AU - McDonnell, James Michael

AU - Sutton, Brian John

AU - Westwood, Marta Katarzyna

PY - 2017/12/14

Y1 - 2017/12/14

N2 - The present invention relates to the area of improved anti-IgE antibodies and antigen binding agents, and compositions thereof, which target IgE, for instance: for use in treating disorders caused by IgE (such as allergic responses, or certain autoimmune responses); and, in particular, disorders caused by the interaction of IgE with the FcεRI receptor. In particular, this invention relates to improved anti-IgE antibodies and antigen binding agents related to novel mutants of omalizumab (Xolair®). The improved anti-IgE antibodies and antigen binding agents of the invention may have improved affinity for IgE and/or an improved interaction with the Cε2 domain of IgE and/or an improved modified epitope on IgE (for instance further involving the Cε2 domain of IgE) and/or the ability to disassociate IgE from the FcεRI receptor for instance at pharmaceutically-relevant concentrations. In one aspect, improved or novel treatments for IgE mediated disorders are disclosed in which IgE is targeted (for instance free IgE and/or IgE complexed with the FcεRI receptor).

AB - The present invention relates to the area of improved anti-IgE antibodies and antigen binding agents, and compositions thereof, which target IgE, for instance: for use in treating disorders caused by IgE (such as allergic responses, or certain autoimmune responses); and, in particular, disorders caused by the interaction of IgE with the FcεRI receptor. In particular, this invention relates to improved anti-IgE antibodies and antigen binding agents related to novel mutants of omalizumab (Xolair®). The improved anti-IgE antibodies and antigen binding agents of the invention may have improved affinity for IgE and/or an improved interaction with the Cε2 domain of IgE and/or an improved modified epitope on IgE (for instance further involving the Cε2 domain of IgE) and/or the ability to disassociate IgE from the FcεRI receptor for instance at pharmaceutically-relevant concentrations. In one aspect, improved or novel treatments for IgE mediated disorders are disclosed in which IgE is targeted (for instance free IgE and/or IgE complexed with the FcεRI receptor).

M3 - Patent

M1 - WO 2017/211928 A1

Y2 - 2017/06/08

ER -

Anti-IgE Antibodies

Abstract

Access to Document

Fingerprint

Cite this